Didier Schils

Didier Schils is a seasoned professional in drug substance development with extensive experience in the pharmaceutical industry. Currently serving as CMC-DS Lead and Director at iTeos Therapeutics since February 2022, Didier Schils oversees drug substance development for small molecules and GMP productions managed by external CDMOs. Prior to this role, Didier Schils held the position of Drug Substance Development Leader at Galapagos, focusing on synthesis development for clinical studies, particularly in cystic fibrosis projects with AbbVie. Experience includes working as Principal Scientist at J&J (API Small Molecule Development), where Didier Schils was instrumental in developing the second-generation process for Canagliflozin, as well as roles in medicinal chemistry and process research at Euroscreen and Janssen Pharmaceutica, contributing to the development of TMC-278, an approved HIV drug. Didier Schils holds a Ph.D. in Organic Chemistry from Université catholique de Louvain.